Predoctoral Training Program in Molecular Pharmacology

分子药理学博士前培训项目

基本信息

  • 批准号:
    9070065
  • 负责人:
  • 金额:
    $ 18.44万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-08-10 至 2021-06-30
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): The primary goal of the Ph.D. Training Program in Molecular Pharmacology and Experimental Therapeutics (MPET) in the Mayo Graduate School is the development of independent investigators capable of directing outstanding research Programs in academia, industry or other settings. The faculty is comprised of 28 well- funded, independent investigators, who focus on a continuum of research areas encompassing studies from basic molecular and genetic aspects of disease through drug discovery and development of novel therapies for cardiovascular and malignant diseases. The faculty provides training opportunities in areas that include computational chemistry, molecular mechanisms of drug action and resistance, metabolomics, novel therapeutic strategies, the genetics of addiction, preclinical and clinical pharmacology, and pharmacogenomics of genes associated with drug responses. Twenty-six predoctoral students are currently enrolled in the MPET Ph.D. training program. A rigorous didactic curriculum includes a series of Core Curriculum courses that ensures a strong fundamental knowledge in biochemistry, molecular biology, genetics, statistics, cell biology and pharmacology and a series of tutorial-based courses to provide students with advanced training in molecular pharmacology. During their first two years of study, students complete at least 3 laboratory rotations and select a laboratory for their thesis research. They si for comprehensive written and oral qualifying examinations at the end of year two. After developing a written thesis proposal delineating the questions and approaches to be pursued in the thesis research, the thesis committee reviews the proposed research at the first committee meeting. Students present work-in-progress updates on their research projects to MPET faculty and students each year. Students are required to publish completed work in a timely manner and encouraged to attend national meetings to present their work. The average time to completion of the Ph.D. Program is 5.2 years. Starting in Year 3 and beyond, students meet with their thesis committees at least twice per year and are mentored to identify outstanding postdoctoral training opportunities as the next step in their career development. Graduates of the MPET Ph.D. training program have outstanding track records. They go on to postdoctoral fellowships, with many now serving as principal investigators in academia and industry. We request 4 positions for the next funding period.


项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LARRY M KARNITZ其他文献

LARRY M KARNITZ的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LARRY M KARNITZ', 18)}}的其他基金

Targeting Chk1 in Acute Myeloid Leukemia
靶向 Chk1 治疗急性髓系白血病
  • 批准号:
    9297247
  • 财政年份:
    2015
  • 资助金额:
    $ 18.44万
  • 项目类别:
Targeting Chk1 in Acute Myeloid Leukemia
靶向 Chk1 治疗急性髓系白血病
  • 批准号:
    9115542
  • 财政年份:
    2015
  • 资助金额:
    $ 18.44万
  • 项目类别:
CDK12 in Ovarian Cancer
CDK12 在卵巢癌中的作用
  • 批准号:
    9035009
  • 财政年份:
    2015
  • 资助金额:
    $ 18.44万
  • 项目类别:
Project 3: Repurposing Ceritinib for Ovarian Cancer Therapy
项目 3:重新利用色瑞替尼治疗卵巢癌
  • 批准号:
    10452721
  • 财政年份:
    2009
  • 资助金额:
    $ 18.44万
  • 项目类别:
Project 3: Repurposing Ceritinib for Ovarian Cancer Therapy
项目 3:重新利用色瑞替尼治疗卵巢癌
  • 批准号:
    10268765
  • 财政年份:
    2009
  • 资助金额:
    $ 18.44万
  • 项目类别:
Predoctoral Training Program in Molecular Pharmacology
分子药理学博士前培训项目
  • 批准号:
    8677598
  • 财政年份:
    2005
  • 资助金额:
    $ 18.44万
  • 项目类别:
Predoctoral Training Program in Molecular Pharmacology
分子药理学博士前培训项目
  • 批准号:
    8851608
  • 财政年份:
    2005
  • 资助金额:
    $ 18.44万
  • 项目类别:
Predoctoral Training Program in Molecular Pharmacology
分子药理学博士前培训项目
  • 批准号:
    8287047
  • 财政年份:
    2005
  • 资助金额:
    $ 18.44万
  • 项目类别:
Predoctoral Training Program in Molecular Pharmacology
分子药理学博士前培训项目
  • 批准号:
    8494058
  • 财政年份:
    2005
  • 资助金额:
    $ 18.44万
  • 项目类别:
Predoctoral Training Program in Molecular Pharmacology
分子药理学博士前培训项目
  • 批准号:
    8015781
  • 财政年份:
    2005
  • 资助金额:
    $ 18.44万
  • 项目类别:

相似海外基金

National Career Development Program for Researchers in Pediatric Clinical Pharmacology
儿科临床药理学研究人员国家职业发展计划
  • 批准号:
    11001312
  • 财政年份:
    2024
  • 资助金额:
    $ 18.44万
  • 项目类别:
Impact of metabotropic glutamate receptor heteromerization on signaling and pharmacology
代谢型谷氨酸受体异聚化对信号传导和药理学的影响
  • 批准号:
    10637938
  • 财政年份:
    2023
  • 资助金额:
    $ 18.44万
  • 项目类别:
PHARMACOLOGY CONSULTING SERVICES
药理学咨询服务
  • 批准号:
    10924442
  • 财政年份:
    2023
  • 资助金额:
    $ 18.44万
  • 项目类别:
Training in Systems Pharmacology and Toxicology (T-SPaT)
系统药理学和毒理学培训 (T-SPaT)
  • 批准号:
    10714918
  • 财政年份:
    2023
  • 资助金额:
    $ 18.44万
  • 项目类别:
Clinical Pharmacology Quality Assurance (CPQA)
临床药理学质量保证(CPQA)
  • 批准号:
    10850504
  • 财政年份:
    2023
  • 资助金额:
    $ 18.44万
  • 项目类别:
Base Title: PREVENT Preclinical Pharmacology and ToxicologyTask Order Title: Nicotine Reduction Therapy Using the Human Monoclonal Antibody ATI-1013
基本标题:预防临床前药理学和毒理学任务订单标题:使用人单克隆抗体 ATI-1013 进行尼古丁减少治疗
  • 批准号:
    10932479
  • 财政年份:
    2023
  • 资助金额:
    $ 18.44万
  • 项目类别:
Pharmacology Consulting Services in relation to Pharmaceutical Development with Pain expertise. 09/12/2023 - 09/11/2024
与具有疼痛专业知识的药物开发相关的药理学咨询服务。
  • 批准号:
    10949065
  • 财政年份:
    2023
  • 资助金额:
    $ 18.44万
  • 项目类别:
Sedatives Pharmacology in Acute Respiratory Distress Syndrome- SPA
急性呼吸窘迫综合征中的镇静药理学 - SPA
  • 批准号:
    491387
  • 财政年份:
    2023
  • 资助金额:
    $ 18.44万
  • 项目类别:
    Fellowship Programs
Understanding the clinical pharmacology of marijuana-tobacco co-administration
了解大麻-烟草联合用药的临床药理学
  • 批准号:
    10660409
  • 财政年份:
    2023
  • 资助金额:
    $ 18.44万
  • 项目类别:
Learning How to Give Casual Explanations for Large Scale Virtual and Morphological Pharmacology
学习如何对大规模虚拟和形态药理学进行随意解释
  • 批准号:
    10713386
  • 财政年份:
    2023
  • 资助金额:
    $ 18.44万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了